In the setting of NF1, inhibition of MAP-Kinase pathway with the so-called MEK inhibitors is a promising option of pharmacological intervention in cases a tumour reduction should be performed; however, it is surgically not possible or associated with too many risks [15, 18, 27]. The gene discussed is NF1; the disease is neoplasm.